CL2007002324A1 - Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular. - Google Patents
Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular.Info
- Publication number
- CL2007002324A1 CL2007002324A1 CL2007002324A CL2007002324A CL2007002324A1 CL 2007002324 A1 CL2007002324 A1 CL 2007002324A1 CL 2007002324 A CL2007002324 A CL 2007002324A CL 2007002324 A CL2007002324 A CL 2007002324A CL 2007002324 A1 CL2007002324 A1 CL 2007002324A1
- Authority
- CL
- Chile
- Prior art keywords
- gaba
- epilepsy
- anxiety
- treat
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos derivados de 1h-quinoli-4-ona; procedimiento de preparación; composición farmacéutica; y su uso para tratar y/o prevenir enfermedades asociadas con la modulación del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, entre otras enfermedades.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06118720A EP1886996A1 (en) | 2006-08-10 | 2006-08-10 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002324A1 true CL2007002324A1 (es) | 2008-01-18 |
Family
ID=37651083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007002324A CL2007002324A1 (es) | 2006-08-10 | 2007-08-09 | Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100168099A1 (es) |
EP (1) | EP1886996A1 (es) |
CN (1) | CN101522630A (es) |
AR (1) | AR062295A1 (es) |
AT (1) | ATE512138T1 (es) |
BR (1) | BRPI0715817A2 (es) |
CL (1) | CL2007002324A1 (es) |
DK (1) | DK2064185T3 (es) |
PT (1) | PT2064185E (es) |
RU (1) | RU2009108361A (es) |
SI (1) | SI2064185T1 (es) |
TW (1) | TW200833665A (es) |
UY (1) | UY30529A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI366565B (en) | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
TWI492943B (zh) | 2008-12-05 | 2015-07-21 | 大塚製藥股份有限公司 | 喹啉酮化合物及藥學組成物(二) |
JP5769504B2 (ja) * | 2010-06-04 | 2015-08-26 | 大塚製薬株式会社 | 医薬 |
SG11201404214QA (en) | 2012-02-03 | 2014-08-28 | Teva Pharma | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
GB9621757D0 (en) * | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
FR2813791B1 (fr) * | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
CA2484308A1 (en) * | 2002-05-14 | 2003-11-27 | The Regents Of The University Of California | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
-
2006
- 2006-08-10 EP EP06118720A patent/EP1886996A1/en not_active Withdrawn
-
2007
- 2007-08-06 TW TW096128818A patent/TW200833665A/zh unknown
- 2007-08-07 UY UY30529A patent/UY30529A1/es unknown
- 2007-08-09 DK DK07788348.6T patent/DK2064185T3/da active
- 2007-08-09 SI SI200730707T patent/SI2064185T1/sl unknown
- 2007-08-09 CL CL2007002324A patent/CL2007002324A1/es unknown
- 2007-08-09 CN CNA2007800365992A patent/CN101522630A/zh active Pending
- 2007-08-09 BR BRPI0715817-3A2A patent/BRPI0715817A2/pt not_active IP Right Cessation
- 2007-08-09 AR ARP070103514A patent/AR062295A1/es unknown
- 2007-08-09 PT PT07788348T patent/PT2064185E/pt unknown
- 2007-08-09 AT AT07788348T patent/ATE512138T1/de active
- 2007-08-09 US US12/377,103 patent/US20100168099A1/en not_active Abandoned
- 2007-08-09 RU RU2009108361/04A patent/RU2009108361A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY30529A1 (es) | 2008-02-29 |
EP1886996A1 (en) | 2008-02-13 |
RU2009108361A (ru) | 2010-09-20 |
TW200833665A (en) | 2008-08-16 |
CN101522630A (zh) | 2009-09-02 |
AR062295A1 (es) | 2008-10-29 |
PT2064185E (pt) | 2011-09-12 |
SI2064185T1 (sl) | 2011-10-28 |
ATE512138T1 (de) | 2011-06-15 |
DK2064185T3 (da) | 2011-09-19 |
US20100168099A1 (en) | 2010-07-01 |
BRPI0715817A2 (pt) | 2014-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013989A (es) | Terapia en combinacion para depresion. | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
NZ591312A (en) | Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
EA202091999A2 (ru) | Применение ингибиторов dpp iv | |
UY29899A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
MY162067A (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
RS52781B (en) | MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS | |
CL2007002324A1 (es) | Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular. | |
MX2008013827A (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual. | |
SI2205244T1 (sl) | Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni | |
BR112014003704A2 (pt) | moduladores ror gama | |
BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
CL2007003065A1 (es) | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros | |
JO3440B1 (ar) | استخدام الأغوميلاتين في تحضير علاجات لمداولة اضطرابات القلق العام. | |
TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
CL2011000184A1 (es) | Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos. | |
CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. |